Sickle Cell Disease: Targeting Alloantibody formation Reduction (STAR) - Risk factors for alloantibody formation

Sickle Cell Disease: Targeting Alloantibody formation Reduction (STAR) - Risk factors for alloantibody formation - STAR

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON41526

Enrollment

300

Registered

2014-07-31

Start date

2014-11-04

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alloimmunisation in blood transfusion recipients

Interventions

None listed

Eligibility

Age

2 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Sickle Cell Disease (phenotypes HbSS, HbSC, HbS*+, HbS*0 or HbSE) - History of at least 1 RBC transfusion in one of the participating centers

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
The primary study parameters are: - Immunogenetic determinants that could determine alloimmunisation; Variations in the gene cluster encoding the Fc-gamma receptors and the SIRP-alpha receptor (Signal Regulatory Protein-alpha). - Clinical determinants that could determine alloimmunisation such as gender, SCD genotype, geographic origin, age, age of first transfusion and number of transfusions. The main study outcome is the cumulative incidence of allo-antibody formation in response to RBC transfusion.	—

Measure

Time frame

The primary study parameters are: - Immunogenetic determinants that could determine alloimmunisation; Variations in the gene cluster encoding the Fc-gamma receptors and the SIRP-alpha receptor (Signal Regulatory Protein-alpha). - Clinical determinants that could determine alloimmunisation such as gender, SCD genotype, geographic origin, age, age of first transfusion and number of transfusions. The main study outcome is the cumulative incidence of allo-antibody formation in response to RBC transfusion.

—

Countries

Netherlands

Outcome results